NCT00193622View on ClinicalTrials.gov

Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site

PHASE2CompletedINTERVENTIONAL

Enrollment

50

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

September 30, 2005

Study Completion Date

January 31, 2009

Conditions

Neoplasms, Unknown Primary

Interventions

DRUG

Bevacizumab

DRUG

Erlotinib

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

SCRI Development Innovations, LLC

OTHER

NCT00193622 - Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site | Biotech Hunter | Biotech Hunter